Checking the medicine / A question brief
Are weight medicines and research peptides the same?
An approved weight medicine, a version made to order, and a product sold for research are different. Ask which one you are being offered.
Which familiar names have approved products?
FDA is the Food and Drug Administration, which reviews the specific medicine and its uses.
As of September 2026, FDA-approved semaglutide medicines include Ozempic and Wegovy; tirzepatide has FDA-approved medicines named Mounjaro and Zepbound.
Ask for both the product name and its form. A familiar ingredient name does not identify what you are being offered.
What changed for pharmacy-made copies?
FDA’s national shortage list no longer includes semaglutide or tirzepatide, as of September 2026. The two are also off FDA’s list of raw ingredients allowed for large businesses that make medicines to order.
A batch compounder, also called an outsourcing facility, makes medicines to order in larger runs.
The shortage list can allow pharmacies to make copies. It can also let large facilities use a raw ingredient missing from the allowed-ingredient list. An empty local shelf does not give those permissions.
FDA’s policy, checked in September 2026, says a copy does not become a different product just because a vitamin is added.
A change can be an exception if the person writing the prescription records an important difference for a named patient.
What about the newer research products?
As of September 2026, retatrutide has no approved drug in the United States.
Cagrilintide is another drug ingredient that FDA has not approved. FDA says in September 2026 that federal law does not allow making medicines to order with retatrutide or cagrilintide.
A trial name or promising advert is not the same as an approved product. Ask exactly which product would be prescribed.